Preventing lung cancer by stopping smoking

Clinics in Chest Medicine

Volumn 23, Issue 1, 2002, Pages 27-36

  Hurt, Richard D ^a   Ebbert, Jon O ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CLONIDINE; NICOTINE; NICOTINE GUM; NORTRIPTYLINE;

AEROSOL; HEALTH SERVICE; HUMAN; INHALER; LUNG CANCER; MEDICAL PRACTICE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT INDICATION;

EID: 0036195582     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-5231(03)00074-1     Document Type: Review

References (56)

1. Primary malignant growths of the lung
2. Cardiovascular toxicity of nicotine: Implications for nicotine replacement therapy
3. Nicotine nasal spray with nicotine patch for smoking cessation: Randomized trial with 6-year follow-up
4. Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: A randomized, double-blind, placebo-controlled trial
5. Bupropion SR as a smoking cessation treatment in remitted depressed patients maintained on selective serotonin reuptake inhibitor antidepressants
6. Effects of transdermal nicotine treatment on structure and function of coronary artery bypass grafts
7. Cost-effectiveness of treating nicotine dependence: The Mayo Clinic experience
8. High-dose nicotine patch therapy: Percentage of replacement and smoking cessation
9. Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for tobacco withdrawal symptoms
10. Physician referral for smoking cessation: Outcome in those who show and don't show
11. Arteriovanous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine
12. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking
13. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism
14. A randomized, controlled trial of sustained-release bupropion for pharmacologic relapse prevention following smoking cessation
15. Residential (inpatient) treatment compared with outpatient treatment for nicotine dependence
16. Higher levels of nicotine in arterial than in venous blood after cigarette smoking
17. The nicotine inhaler in smoking cessation
18. Treatment of nicotine dependence: Is more better?
19. Are higher doses of nicotine replacement more effective for smoking cessation?
20. Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up: One-year outcome and percentage nicotine replacement
21. Serum nicotine and cotinine levels during nicotine patch therapy
22. Temporal effects of nicotine nasal spray and gum on nicotine withdrawal symptoms
23. Prying open the door to the tobacco industry's secrets about nicotine: The Minnesota Tobacco Trial
24. A comparison of sustained-release bupropion and placebo for smoking cessation
25. Bupropion for pharmacologic relapse prevention to smoking: Predictors of outcome
26. Is there a common etiology for the rising incidence of and decreasing survival with adenocarcinoma of the lung?
27. A 102-center prospective study of seizure in association with bupropion
28. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
29. Varying nicotine patch dose and type of smoking cessation counseling
30. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease
31. Predicting smoking cessation: Who will quit with and without the nicotine patch?
32. Combined use of nicotine patch and gum in smoking cessation: A placebo-controlled clinical trial
33. Smokers' misperceptions of light and ultralight cigarettes may keep them smoking
34. Application of serum nicotine and plasma cotinine concentrations to assess nicotine replacement in light, moderate, and heavy smokers undergoing transdermal therapy
35. Site of nicotine absorption from a vapour inhaler: Comparison with cigarette smoking
36. Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia
37. Actual causes of death in the United States
38. The tar in cigarette smoke and its possible effects
39. Carcinoma of the lung
40. Importance of baseline cotinine plasma values in smoking cessation: Results from a double-blind study with nicotine patch
41. Stages and processes of self-change of smoking: Toward an integrative model of change
42. Clinical use of nicotine chewing gum
43. Percent serum replacement and success of nicotine patch therapy
44. Nicotine nasal spray and vapor inhaler: Abuse liability assessment
45. Randomized, controlled trial of nasal nicotine spray in smoking cessation
46. In the 1800s, antismoking was a burning issue
47. Is transdermal nicotine associated with cardiovascular risk?
48. Higher dosage nicotine patches increase 1-year smoking cessation rates: Results from the European CEASE trial
49. Tobacco withdrawal and nicotine replacement influence objective measures of sleep
50. Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma
51. Dose-related cardiovascular and endocrine effects of transdermal nicotine